Amylyx Pharmaceuticals (AMLX) Cash from Investing Activities (2021 - 2026)

Amylyx Pharmaceuticals' Cash from Investing Activities history runs 6 years deep, the most recent figure standing at $36.3 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities rose 183.06% year-over-year to $36.3 million in Q1 2026; TTM through Mar 2026 was $94.0 million, a 201.39% increase from a year earlier, with the FY2025 full-year figure at $14.0 million, down 81.44% from the prior year.
• Cash from Investing Activities improved to $36.3 million in Q1 2026 per AMLX's latest filing, from $29.5 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $123.2 million in Q2 2023 and bottomed at -$228.2 million in Q4 2022.
• The 5-year median for Cash from Investing Activities is $20.9 million (2023), against an average of -$1.2 million.
• Across the five-year window, Cash from Investing Activities tumbled 709264.29% in 2022 and jumped 2661.59% in 2023, its largest moves.
• Year by year, Cash from Investing Activities stood at -$228.2 million in 2022, then surged by 109.17% to $20.9 million in 2023, then soared by 210.54% to $65.0 million in 2024, then slumped by 54.65% to $29.5 million in 2025, then grew by 23.06% to $36.3 million in 2026.
• Per Business Quant, the three latest AMLX Cash from Investing Activities figures stand at $36.3 million (Q1 2026), $29.5 million (Q4 2025), and $5.2 million (Q3 2025).